Mutations in the KRAS gene are an early event in the development of CRC and KRAS activation promotes cell proliferation, survival and metastasis by constitutively activating MAPK/ERK, PI3K/AKT, and NF-kB signaling pathways [11, 47]. This evidence concerns the gene KRAS and colorectal carcinoma.